Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Homologous Recombination Deficiency: early-phase trial registry
4 of 4 indexed Homologous Recombination Deficiency trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · 4 currently recruiting · #4,115 of 28,707 conditions by registered trial count
Homologous Recombination Deficiency: 4 US clinical trials tracked, 4 recruiting.
Homologous Recombination Deficiency is the subject of 4 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is AtlasMedx, Incorporated, running 1 of these trials.
Enrollment posture brief
Registry condition homologous-recombination-deficiency
OPEN 4 | RECR 100% | LATE 0 | EARLY 4 | RANK #4115 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)
Homologous Recombination Deficiency lists 4 open slots (100% of 4 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Homologous Recombination Deficiency on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Homologous Recombination Deficiency is recruiting above its size-band peers.
4 of 4 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
4 total, page 1 of 1
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
NCT06545942
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
Eisbach Bio
NCT06525298
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
AtlasMedx, Incorporated
NCT04503265
Olaparib in Patients With HRD Malignant Mesothelioma
University of Chicago
NCT04515836
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Homologous Recombination Deficiency records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Homologous Recombination Deficiency trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Homologous Recombination Deficiency page
4 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Homologous Recombination Deficiency trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AtlasMedx, Incorporated sponsors the most Homologous Recombination Deficiency trials on record, review their full trial history before evaluating a specific study. See AtlasMedx, Incorporated's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Homologous Recombination Deficiency condition card totals 4 registered trials; most-linked intervention Olaparib; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.